Search - tctmd.com

Displaying 261 - 280 of 2612

Sort: Relevancy | Date

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

December 05, 2023

Short DAPT May Be Especially Beneficial for Women at High Bleeding Risk

News Daily News

Short DAPT May Be Especially Beneficial for Women at High Bleeding Risk

Yael L. Maxwell

November 30, 2023

TCTMD’s Top 10 Most Popular Stories for November 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

November 30, 2023

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

News Daily News

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

Michael O'Riordan

November 27, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

News Daily News

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

Yael L. Maxwell

November 08, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

News Conference News TCT 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Yael L. Maxwell

November 06, 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

News Conference News TCT 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

October 26, 2023

AF Patients at Highest Bleeding Risks: How Should We Individualize Postimplant Medical Therapy?

Presentation TCT 2023

AF Patients at Highest Bleeding Risks: How Should We Individualize Postimplant Medical Therapy?

Presenter: Edip Gurol

October 26, 2023

Novel Solutions for High Bleeding Risk Patients

Presentation TCT 2023

Novel Solutions for High Bleeding Risk Patients

Presenter: Bjorn Redfors

October 26, 2023

TCT 202: Frailty Based Prediction of Major Bleeding Risk in Patients Undergoing TAVI: a POPular TAVI sub-analysis

Presentation TCT 2023

TCT 202: Frailty Based Prediction of Major Bleeding Risk in Patients Undergoing TAVI: a POPular TAVI sub-analysis

Presenter: Dirk Jan van Ginkel

October 25, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.